ISRCTN74123635 https://doi.org/10.1186/ISRCTN74123635

Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration

Submission date
09/05/2005

Recruitment status
No longer recruiting

Registration date
16/05/2005

Overall study status
Completed

Last Edited
18/02/2008

Condition category
Eye Diseases

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ricardo Agurto-Rivera

Contact details
Exequiel Fernández nº 920
Casa F
Ñuñoa
Santiago
Chile
+56 8 5021968
ricardo_agurto@yahoo.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Study objectives
TTT plus intravitreous triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Age-Related Macular Degeneration (ARMD) not available for current therapies

Interventions
Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreous Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)

Triamcinolone

Primary outcome measure
Preservation of visual acuity

Secondary outcome measures
Closure of CNV, OCT characteristics

Overall study start date
01/02/2004

Completion date
28/02/2006

Eligibility

Key inclusion criteria
Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
200

Key exclusion criteria
1. Any patient that has indication for PDT and has the economical means to get this therapy
2. Media opacity
3. Previous treatment for CNV

Date of first enrolment
01/02/2004

Date of final enrolment
28/02/2006

Locations

Countries of recruitment
Chile

Mexico

Study participating centre
Exequiel Fernández nº 920
Santiago
Chile

Sponsor information

Organisation
Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

Sponsor details
Vicente García Torres Nº 46
Barrio San Lucas
Del Coyoacán
Mexico City
Mexico
04030
+52 10841400
retinamex@yahoo.com

Sponsor type
Not defined

ROR
https://ror.org/03sgfhr82

Funder(s)

Funder type
Charity

Funder Name
Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	25/11/2005		Yes	No